This is a pre-revenue clinical-stage biotech press release with no financial data — the stock movement will depend on investor perception of ERNA-101's probability of success. Monitor for the Q3 2026 IND submission and any partnership or financing announcements that could extend the cash runway.
Price Chart
Executive Summary
Ernexa Therapeutics provided a business update press release highlighting progress on its lead candidate ERNA-101, including completion of process development and transition to GMP manufacturing, with an IND submission targeted for Q3 2026. No financial results were reported, and the company remains pre-revenue with a $13M market cap and a consensus EPS estimate of -$2.11 for the next quarter.
Key Financial Metrics
Key Facts
- IND submission for ERNA-101 targeted for Q3 2026
- Process development for ERNA-101 manufacturing successfully completed
- Transition to GMP manufacturing underway
- Technology transfer activities in progress
- Company advancing toward becoming a clinical-stage biotechnology company
- Reported EPS for Q3 2023 was -$1.03 vs consensus of -$2.11 (51.2% beat), but this is a stale period
- Market cap is $13M with 0% analyst bullish rating (3 Hold, 1 Sell, 2 Strong Sell)
Financial Impact
No financial data reported; company is pre-revenue with $0 consensus revenue estimate
Risk Factors
- Pre-revenue company with no approved products — high binary risk around IND clearance and clinical trial outcomes
- Cash runway not disclosed; may require dilutive financing before reaching clinical milestones
- Weak analyst sentiment (0% bullish, 3 Hold, 1 Sell, 2 Strong Sell) and tiny market cap ($13M) suggest limited institutional support
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301925 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Press Release | $2.08 | awaiting T+5 | — | $2.06 (−0.66%) |
Oct 15, 2026 11d ago | 8-K | $2.09 $2.07 | ▼ −1.20% | ▼ −0.77% | $2.06 (−1.37%) |
Oct 1, 2026 26d ago | Press Release | $2.96 $2.49 | ▼ −15.88% | ▼ −17.18% | $2.06 (−30.36%) |
Sep 30, 2026 27d ago | Press Release | $3.20 $2.39 | ▼ −25.31% | ▼ −27.23% | $2.06 (−35.58%) |
Sep 16, 2026 5w ago | 8-K | $3.76 $3.62 | ▼ −3.72% | ▼ −4.32% | $2.06 (−45.18%) |
Sep 16, 2026 5w ago | 8-K | $3.76 $3.62 | ▼ −3.72% | ▼ −4.32% | $2.06 (−45.18%) |
Jul 14, 2026 15w ago | Press Release | $6.06 $5.43 | ▼ −10.40% | ▼ −9.10% | $2.06 (−65.98%) |
Jun 26, 2026 17w ago | 8-K | $7.03 $6.44 | ▼ −8.39% | ▼ −9.78% | $2.06 (−70.68%) |
Jun 17, 2026 18w ago | Press Release | $5.89 $6.30 | ▲ +6.96% | ▲ +8.00% | $2.06 (−65.00%) |
May 27, 2026 21w ago | Press Release | $11.14 $8.00 | ▼ −28.19% | ▼ −29.39% | $2.06 (−81.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers